Posts by Mourabit Halima

The PERLA trial results demonstrated that Dostarlimab plus chemotherapy achieved better overall survival (OS) compared to pembrolizumab plus chemotherapy in advanced non-small cell lung cancer (NSCLC), with a median OS of 20.2 months vs. 15.9 months.

Editorial Note: Quality control has become an increasingly critical focus in breast cancer diagnosis and treatment. As China enhances its cancer prevention and control framework, the standardization of breast cancer care is receiving growing attention. At the 2024 Conference on Standardized Diagnosis and Quality Control in Breast Cancer, Dr. Jin Yang from The First Affiliated Hospital Xi'an Jiao Tong University presented a comprehensive report titled Quality Control in Breast Cancer Care and National Performance Indicators. In an exclusive interview with Oncology Frontier, Professor Yang provided in-depth insights into the content, significance, and implementation challenges of these quality control measures, illuminating the path forward for breast cancer diagnosis and treatment in China.

From November 15 to 17, 2024, the Chinese Congress on Holistic Integrative Oncology (CCHIO)(CCHIO) was held in Xi’an under the theme "Winning in Integration: Tumor Prevention and Treatment." In the breast cancer domain, the conference integrated the latest global advancements in diagnosis, treatment, and research. At the event, Oncology Frontier interviewed Dr. Jin Zhang, Chair of The Chinese Anti-Cancer Association, Committee of Breast Cancer Society (CACA-CBCS) and a renowned expert from Tianjin Medical University Cancer Institute and Hospital. Professor Zhang shared her insights into the development of breast oncology in China, focusing on HR-positive breast cancer, and discussed the current landscape and future of precision diagnosis and treatment in this area.

At the recent The 9th Congress of the Chinese Chapter of the International Hepato-Pancreato-Biliary Association (CCIHPBA), Prof. Chaoliu Dai from Shengjing Hospital of China Medical University presented on “Controlling Intraoperative Hemorrhage and Protecting Residual Liver Function in Hepatectomy.” Oncology frontier invited Prof. Dai to delve further into this topic and share insights from his presentation.

The 2024 CACA Integrated Lung Cancer Conference, hosted by the Chinese Anti-Cancer Association, was held in Zhuhai from October 25 to 26. Focusing on the theme “Gathering Strength, Leading the Future,” the conference brought together prominent experts in the field of lung cancer to discuss critical issues and advancements. Oncology frontier interviewed Dr. Weimin Li from West China Hospital, Sichuan University, who shared insights on the progress and future outlook of precision lung cancer screening in China.

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting has successfully concluded, showcasing groundbreaking oncology research. Dr. Chang Liu from Professor Lin Shen’s team at Peking University Cancer Hospital presented their study on the efficacy and safety of CCR8 monoclonal antibody LM-108 combined with PD-1 antibody in gastric cancer patients. Professor Shen’s presentation at ASCO sparked significant industry interest. Oncology Frontier invited Dr. Chang Liu to provide an in-depth analysis of this study’s breakthroughs and significance.